701 results on '"Griffith, David E"'
Search Results
2. Diagnostic Criteria and the Decision to Treat Nontuberculous Mycobacterial Pulmonary Disease
3. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
4. Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease
5. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases
6. Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals.
7. Treatment of Mycobacterium abscessus Pulmonary Disease
8. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure
9. Managing Mycobacterium avium Complex Lung Disease With a Little Help From My Friend
10. Nontuberculous Mycobacterial Disease: An Introduction and Historical Perspective
11. Disease Caused by Mycobacterium Abscessus and Other Rapidly Growing Mycobacteria (RGM)
12. Nontuberculous Mycobacterial Disease Management Principles
13. Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study
14. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians’ Interpretation of a US Food and Drug Administration Workshop
15. Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects.
16. Potential Outbreak of Extrapulmonary Mycobacterium abscessus subspecies massiliense Infections from Stem Cell Treatment Clinics in Mexico--Arizona and Colorado, 2022
17. Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation
18. Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry
19. Notes from the Field: Potential Outbreak of Extrapulmonary Mycobacterium abscessus subspecies massiliense Infections from Stem Cell Treatment Clinics in Mexico — Arizona and Colorado, 2022
20. Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
21. Nontuberculous mycobacteria
22. Mycobacterium abscessus and Antibiotic Resistance : Same As It Ever Was
23. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease
24. Antimycobacterial Consideration in Transplantation Including Drug Non-susceptibility and Resistance: Tuberculosis and Nontuberculous Mycobacterial Disease
25. Analysis of alpha‐1‐antitrypsin (AAT)‐regulated, glucocorticoid receptor‐dependent genes in macrophages reveals a novel host defense function of AAT.
26. Medical Management of Pulmonary Nontuberculous Mycobacterial Disease
27. Management and diagnosis of tuberculosis in solid organ transplant candidates and recipients: Expert survey and updated review,
28. Thrice-Weekly Clarithromycin-Containing Regimen for Treatment of Mycobacterium kansasii Lung Disease: Results of a Preliminary Study
29. Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry
30. Azithromycin-Containing Regimens for Treatment of Mycobacterium avium Complex Lung Disease
31. The Challenge and Opportunity of New Clinical Infectious Entities
32. Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
33. Early Results (at 6 Months) with Intermittent Clarithromycin-Including Regimens for Lung Disease Due to Mycobacterium avium Complex
34. Relationship of Adverse Events to Serum Drug Levels in Patients Receiving High-Dose Azithromycin for Mycobacterial Lung Disease
35. Azithromycin Activity against Mycobacterium avium Complex Lung Disease in Patients Who Were Not Infected with Human Immunodeficiency Virus
36. Postcesarean section wound infection caused by Mycobacterium massiliense
37. Nontuberculous Mycobacterial Disease: An Introduction and Historical Perspective
38. Nontuberculous Mycobacterial Disease Management Principles
39. Disease Caused by Mycobacterium Abscessus and Other Rapidly Growing Mycobacteria (RGM)
40. Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease
41. The Significance of Mycobacterium abscessus Subspecies abscessus Isolation During Mycobacterium avium Complex Lung Disease Therapy
42. Treatment of Slowly Growing Mycobacteria
43. Macrolide/Azalide Therapy for Nodular/Bronchiectatic Mycobacterium avium Complex Lung Disease
44. Nontuberculous mycobacterial (NTM) lung disease: The top ten essentials
45. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis
46. 55 - Infecciones por micobacterias no tuberculosas
47. Ex vivo and in vivo evidence that cigarette smoke-exposed T regulatory cells impair host immunity against Mycobacterium tuberculosis.
48. Sputum Detection of Predisposing Genetic Mutations in Women with Pulmonary Nontuberculous Mycobacterial Disease
49. α1-Antitrypsin Binds to the Glucocorticoid Receptor with Anti-Inflammatory and Antimycobacterial Significance in Macrophages
50. First Do No Harm—Adverse Events, Drug Intolerance, and Hepatotoxicity: How Can We Not Justify Directly Observed Therapy for Treating Tuberculosis?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.